Literature DB >> 16424031

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.

Nelson C Di Paolo1, Sebastian Tuve, Shaoheng Ni, Karl Erik Hellström, Ingegerd Hellström, André Lieber.   

Abstract

Heat shock proteins such as gp96 have the ability to chaperone peptides and activate antigen-presenting cells. In this study, we tested whether adenovirus-mediated overexpression of secreted or membrane-associated forms of gp96 in tumor cells would stimulate an antitumor immune response. Studies were carried out in C57Bl/6 mice bearing aggressively growing s.c. tumors derived from syngeneic TC-1 cells, a cell line that expresses HPV16 E6 and E7 proteins. We found that secreted gp96 can induce protective and therapeutic antitumor immune responses. Our data also indicate that the antitumor effect of sgp96 expression seems to be limited by the induction of suppressive regulatory T cells (Treg). TC-1 tumor transplantation increased the number of splenic and tumor-infiltrating Tregs. Importantly, treatment of mice with low-dose cyclophosphamide decreased the number of Tregs and enhanced the immunostimulatory effect of sgp96 expression. We also tested whether an oncolytic vector (Ad.IR-E1A/TRAIL), that is able to induce tumor cell apoptosis and, potentially, release cryptic tumor epitopes in immunogenic form, could stimulate antitumor immune responses. Although tumor cells infected ex vivo with Ad.IR-E1A/TRAIL had no antitumor effect when used as a vaccine alone, the additional treatment with low-dose cyclophosphamide resulted in the elimination of pre-established tumors. This study gives a rationale for testing approaches that suppress Tregs in combination with oncolytic or immunostimulatory vectors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424031      PMCID: PMC1360184          DOI: 10.1158/0008-5472.CAN-05-2388

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB.

Authors:  L Polak; H Geleick; J L Turk
Journal:  Immunology       Date:  1975-05       Impact factor: 7.397

Review 2.  Induction of tolerogenic DCs: 'you are what you eat'.

Authors:  Karsten Mahnke; Juergen Knop; Alexander H Enk
Journal:  Trends Immunol       Date:  2003-12       Impact factor: 16.687

3.  Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Anuj Gaggar; Helen Gharwan; Vladimir Ternovoi; Volker Sandig; André Lieber
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide.

Authors:  M Glaser
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

5.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Authors:  François Ghiringhelli; Nicolas Larmonier; Elise Schmitt; Arnaud Parcellier; Dominique Cathelin; Carmen Garrido; Bruno Chauffert; Eric Solary; Bernard Bonnotte; François Martin
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

6.  Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.

Authors:  Wenhong Ren; Randy Strube; Xiaoqing Zhang; Si-Yi Chen; Xue F Huang
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

7.  A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine.

Authors:  Xue F Huang; Wenhong Ren; Lisa Rollins; Pauline Pittman; Molik Shah; Lei Shen; Qinlong Gu; Randy Strube; Fang Hu; Si-Yi Chen
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

8.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

9.  Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus.

Authors:  J Lindenmann; P A Klein
Journal:  J Exp Med       Date:  1967-07-01       Impact factor: 14.307

10.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.

Authors:  M Röllinghoff; A Starzinski-Powitz; K Pfizenmaier; H Wagner
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  26 in total

1.  Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Authors:  Candice Willmon; Rosa M Diaz; Phonphimon Wongthida; Feorillo Galivo; Timothy Kottke; Jill Thompson; Steven Albelda; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

2.  E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.

Authors:  S C Cheong; Y Wang; J-H Meng; R Hill; K Sweeney; D Kirn; N R Lemoine; G Halldén
Journal:  Cancer Gene Ther       Date:  2007-11-23       Impact factor: 5.987

Review 3.  Intelligent design: combination therapy with oncolytic viruses.

Authors:  Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2009-12-22       Impact factor: 11.454

4.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

5.  Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

Authors:  Maria A Thomas; Jacqueline F Spencer; Karoly Toth; John E Sagartz; Nancy J Phillips; William S M Wold
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

6.  Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.

Authors:  Pu Liu; Jade Jaffar; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

7.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

8.  Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.

Authors:  G Ungerechts; M E Frenzke; K-C Yaiw; T Miest; P B Johnston; R Cattaneo
Journal:  Gene Ther       Date:  2010-08-05       Impact factor: 5.250

9.  Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.

Authors:  Joshua P Landreneau; Michael R Shurin; Marianna V Agassandian; Anton A Keskinov; Yang Ma; Galina V Shurin
Journal:  Cancer Microenviron       Date:  2013-11-29

10.  Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model.

Authors:  Rakhee Sachdeva; Akhil C Banerjea; Nancy Malla; Mohan Lal Dubey
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.